Merck’s Estimates Boosted at UBS; Sees Victrelis as a Catalyst (MRK)

By
A A A
Share |

Drugmaker Merck & Co., Inc. ( MRK ) on Thursday saw its earnings estimates boosted by analysts at UBS, based on the introduction of its new hepatitis C treatment, Victrelis.

The firm said it raised its estimates for MRK through 2011, while maintaining its "Buy" rating and $42 price target. That target suggests a healthy 18% upside to the stock's Wednesday closing price of $35.53.

Merck shares were mostly flat in premarket trading Thursday.

The Bottom Line
Shares of Merck ( MRK ) have a 4.28% dividend yield, based on last night's closing stock price of $25.53. The stock has technical support in the $32 price area. If the shares can firm up, we see overhead resistance around the $37-$38 price levels.

Merck & Co., Inc. ( MRK ) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Created by Dividend.com


This article appears in: Investing , Stocks

Referenced Stocks:

Dividend.com

Dividend.com

More from Dividend.com:

Related Videos

Stocks

Referenced

Most Active by Volume

57,375,820
  • $16.20 ▼ 0.80%
46,357,695
  • $102.13 ▲ 1.23%
39,856,106
  • $3.59 ▲ 0.84%
36,749,915
  • $19.21 ▲ 5.38%
35,094,671
  • $74.63 ▼ 1.75%
25,538,058
  • $48.06 ▼ 0.23%
24,241,250
  • $38.18 ▲ 1.03%
22,422,839
  • $11.20 ▲ 3.70%
As of 8/27/2014, 04:02 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com